Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033
23. August 2024 11:51 ET
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Cancer Cachexia Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global cancer cachexia market is forecast to...
[Latest] Global Cancer Cachexia Market Size/Share Worth USD 5.1 Billion by 2033 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
03. Mai 2024 04:30 ET
|
Custom Market Insights
Austin, TX, USA, May 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cachexia Market Size, Trends and Insights By Therapeutics (Progestogen,...
Global Clinical Nutrition For Cancer Care Report 2024-2030, by Product (Oral, Nutrition Enteral Feeding Formulas, Parenteral Nutrition), Stage, Sales Channel, Region and Segment Forecasts
11. April 2024 04:23 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Nutrition For Cancer Care Market Size, Share & Trends Analysis Report by Product (Oral, Nutrition Enteral Feeding Formulas,...
Cancer Cachexia Global Strategic Research Report 2024: Market to Reach $3.5 Billion by 2030, Driven by Promising Treatment Options
05. April 2024 09:27 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Cancer Cachexia - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Cancer Cachexia Market to Reach...
Global Cancer Cachexia Market Worth $2.85 Billion by 2029: Combination Therapies Gaining Traction
20. März 2024 11:13 ET
|
Research and Markets
Dublin, March 20, 2024 (GLOBE NEWSWIRE) -- The "Cancer Cachexia Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. This research report sheds light...
Actimed Therapeutics Appoints Martin Walton as Chief Financial Officer
19. Oktober 2023 03:00 ET
|
Actimed Therapeutics
London, UK – 19th October 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
IGC Launches Phytocannabinoid Development Committee to Secure Preclinical Initiatives for IGC-501, IGC-502 and IGC-504
13. Februar 2017 06:00 ET
|
India Globalization Capital
BETHESDA, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) announces today that its Phytocannabinoid Development Committee has started its review of...
IGC Provides Update on Phytocannabinoid IP Portfolio
02. November 2016 09:32 ET
|
India Globalization Capital
BETHESDA, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces updates for five patents related to method and treatment of pain, seizures and eating...
IGC Announces Financial Results for Quarter Ended June 30, 2016
17. August 2016 08:00 ET
|
India Globalization Capital
BETHESDA, Md., Aug. 17, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces financial results for the quarter ended June 30, 2016. Total revenue was $288,493 for...
IGC Announces Financial Results for Fiscal Year Ended March 31, 2016
18. Juli 2016 08:30 ET
|
India Globalization Capital
BETHESDA, Md., July 18, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces financial results for the fiscal year ended March 31, 2016. Total revenue was...